We've had a lot of enquiries about the availability of Molnupiravir which is the new Merck/Ridgeback drug that has shown promising results in COVID-19, reducing the chance of hospitalisation by 50%.
That 50% number is based on only 775 patients, but that said, Sofosbuvir was FDA approved based on the results of only ~1000 patients. Interestingly Molnupiravir started its life at Pharmasset along side PSI-7977 (aka Sofosbuvir). Development was abandonded over concerns it was mutagenic and might cause birth defects. You can read more about the history of Mulnupiravir here: